Selective Tumor Hypoxia Targeting Using M75 Antibody Conjugated Photothermally Active MoO_x Nanoparticles.

ABSTRACT: Photothermal therapy (PTT) mediated at the nanoscale has a unique advantage over currently used cancer treatments, by being spatially highly specific and minimally invasive. Although PTT combats traditional tumor treatment approaches, its clinical implementation has not yet been successful. The reasons for its disadvantage include an insufficient treatment efficiency or low tumor accumulation. Here, we present a promising new PTT platform combining a recently emerged two-dimensional (2D) inorganic nanomaterial, MoO_x, and a tumor hypoxia targeting element, the monoclonal antibody M75. M75 specifically binds to carbonic anhydrase IX (CAIX), a hypoxia marker associated with many solid tumors with a poor prognosis. The as-prepared nanoconjugates showed highly specific binding

SUBMITTER: Annusova A 

PROVIDER: S-EPMC10688043 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature